Vendor Selection & FAT/SAT for AIS: What to Prove Before IQ



Vendor Selection & FAT/SAT for AIS: What to Prove Before IQ

Published on 26/11/2025

Vendor Selection & FAT/SAT for AIS: What to Prove Before IQ

Introduction to Automated Inspection Systems (AIS)

Automated Inspection Systems (AIS) have become integral in maintaining quality assurance in pharmaceutical manufacturing. As regulatory expectations from organizations like the FDA, EMA, and MHRA evolve, selecting a qualified vendor and performing thorough Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT) are critical steps in the validation lifecycle. This guide aims to provide a comprehensive overview of the vendor selection process and the subsequent FAT/SAT activities necessary before proceeding with Installation Qualification (IQ).

Understanding the nuances of vendor selection, alongside FAT and SAT, is essential for establishing an effective workflow in visual inspection qualification. The goal of this tutorial is to offer a step-by-step approach that helps pharma professionals grasp the underlying principles and requirements for validating AIS.

Step 1: Defining User Requirements Specification (URS)

The first step in the vendor selection process involves developing a thorough User Requirements Specification (URS). A well-constructed URS serves as a foundational document outlining the technical and operational requirements for AIS. It should reflect compliance with both internal quality standards and external regulatory requirements, such as Annex 1 guidelines pertaining to sterile medicinal products.

  • Identify Key Stakeholders: Engage relevant stakeholders, including Quality Assurance (QA), Quality Control (QC), production, and regulatory affairs teams, to define the expectations for the system.
  • Detail Functional Requirements: Clearly outline the functionality expected from the AIS, such as detection capabilities, false reject rates, and integration with existing systems.
  • Compliance Check: Ensure the stated requirements address all pertinent cGMP and regulatory compliance frameworks, including any relevant clauses from 21 CFR Part 11 for electronic records and signatures.

A comprehensive URS not only guides vendor selection but also serves as a benchmark for evaluating potential systems during FAT/SAT phases.

Step 2: Vendor Selection and Qualification

Once the URS is established, the next phase involves selecting an appropriate vendor. This process should encompass a systematic evaluation of potential suppliers against the defined URS criteria.

  • Market Research: Conduct thorough market research to identify potential vendors known for AIS capabilities. Consider their experience, reputation, and testimonials within the pharmaceutical industry.
  • Request for Proposal (RFP): Develop an RFP that outlines your requirements and solicits proposals from shortlisted vendors. Aim for detailed responses that demonstrate how their machines address functional requirements outlined in the URS.
  • Vendor Audits: Perform onsite or remote audits of the vendor’s facilities. Ensure compliance with relevant ISO standards and observe manufacturing processes to assess capability and reliability.

The vendor should also be capable of providing a defect library and challenge sets essential for the qualification processes of AIS. A robust vendor evaluation method allows companies to identify a partner that meets their operational and compliance needs effectively.

Step 3: Factory Acceptance Testing (FAT)

The FAT phase is critical for confirming that the AIS meets the specifications outlined in the URS before it is shipped to the site. This process should be governed by a well-defined protocol that includes the following elements:

  • Test Environment Setup: Ensure that the testing environment mirrors the conditions expected at the installation site, considering factors such as lighting, temperature, and noise levels.
  • Verification of Functional Requirements: Conduct testing to verify that all functional requirements of the system are met. This may include various types of inspections and measurements to analyze the system’s capabilities.
  • Document Results: Keep detailed records of all tests performed during FAT, including test conditions, results, deviations, and corrective actions taken. This documentation is essential for validating that the system is ready for deployment.

Additionally, validation of the software components must adhere to 21 CFR Part 11, ensuring compliance for electronic records and ensuring that the system operates correctly prior to transport.

Step 4: Site Acceptance Testing (SAT)

Upon arrival of the AIS at the installation site, the SAT phase begins. This phase aims to validate that the system operates according to specifications within the actual manufacturing environment. Essential steps for effective SAT include:

  • Installation Review: Confirm that the AIS has been installed correctly as per the vendor’s specifications and the URS.
  • Performance Verification: Conduct tests similar to FAT to ensure all functionalities meet the defined standards in real-world conditions.
  • Training: Ensure relevant personnel receive adequate training on the operation of the AIS, covering troubleshooting, maintenance, and routine checks.

As with FAT, all SAT results should be documented meticulously, including any discrepancies from expected outcomes, which may warrant re-testing or adjustments. This step is essential in establishing a clear operational baseline for future Reference.

Step 5: Installation Qualification (IQ)

Following successful completion of the SAT, the next phase is Installation Qualification (IQ). This stage confirms that the AIS is installed correctly and operates within predetermined parameters. The IQ protocol should include the following:

  • Documentation Review: Verify that all relevant documents such as the URS, FAT, and SAT reports are complete and readily accessible.
  • System Configuration: Ensure all necessary configurations and settings are suitable for your operational requirements. This includes user permissions and electronic security controls as per 21 CFR Part 11.
  • Procedure Validation: Review operating procedures to confirm they align with machine capabilities and user training.

Documenting the IQ process provides important evidence of compliance and readiness for further qualification stages such as Operational Qualification (OQ) and Performance Qualification (PQ).

Step 6: Ongoing Qualification and Continuous Monitoring

Post-IQ, organizations must focus on Operational Qualification (OQ) and Performance Qualification (PQ) to ensure the system maintains its desired operational state. OQ verifies that the system operates according to the specifications across limit conditions, while PQ ensures it performs effectively over time.

  • Regular System Checks: Develop a routine check schedule to monitor the AIS performance and detect any discrepancies in operation.
  • Trend Analysis: Maintain logs of performance metrics over time to identify trends and areas requiring adjustments or interventions, thus supporting continuous improvement of the inspection process.
  • Change Control Procedures: Implement a robust change control process for handling modifications in the AIS environment or system configurations. This is key in ensuring ongoing compliance and addressing potential regulatory concerns.

Establishing a cycle for reviews and audits further aids in maintaining compliance with evolving regulatory standards like those outlined in Annex 15 of the EU GMP guidelines.

Conclusion

Incorporating a structured approach for vendor selection and FAT/SAT phases is vital for the successful integration of Automated Inspection Systems (AIS) within pharmaceutical operations. By thoroughly addressing the URS, employing a systematic vendor selection process, and performing comprehensive FAT/SAT, companies can ensure that their AIS not only meets but exceeds regulatory compliance expectations. As the pharmaceutical industry continues to evolve, maintaining rigorous quality standards through these validation strategies will remain crucial in delivering safe and effective medicinal products to the market.

By adhering to the principles outlined in this tutorial, professionals in QA, QC, and regulatory affairs can confidently navigate the complexities of AIS validation, enhancing both their operational efficiency and compliance posture.